The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells

被引：0
作者：
D Saulep-Easton
F B Vincent
P S Quah
A Wei
S B Ting
C M Croce
C Tam
F Mackay
机构：
[1] Monash University Central Clinical School,Department of Immunology
[2] Alfred Medical Research and Education Precinct (AMREP),Department of Haematology
[3] The Alfred Hospital,Division of Blood Cancers, Department of Medicine
[4] Australian Centre for Blood Diseases,Department of Molecular Virology
[5] Monash University Central Clinical School,Department of Haematology
[6] Alfred Medical Research and Education Precinct (AMREP),undefined
[7] Immunology and Medical Genetics,undefined
[8] The Ohio State University,undefined
[9] Peter MacCallum Cancer Centre,undefined
[10] St. Andrews’s Place,undefined
来源：
Leukemia | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Interleukin (IL)-10-producing B cells (B10 cells) have emerged as important regulatory elements with immunosuppressive roles. Chronic lymphocytic leukemia (CLL) B cells also secrete IL-10 and share features of B10 cells, suggesting a possible contribution of CLL B cells to immunosuppression in CLL patients. Factors controlling the emergence of B10 cells are not known. B-cell-activating factor of the tumor necrosis factor (TNF) family (BAFF) is critical for B-cell maturation and survival, and is implicated in the development and progression of CLL. We sought to investigate the role of BAFF in the emergence of IL-10-producing regulatory B cells in healthy donors and CLL patients. Here, we report that BAFF signaling promotes IL-10 production by CLL B cells in a mouse model of CLL and in CLL patients. Moreover, BAFF-mediated IL-10 production by normal and CLL B cells is mediated via its receptor transmembrane activator and cyclophilin ligand interactor. Our work uncovered a major targetable pathway important for the generation of regulatory B cells that is detrimental to immunity in CLL.
引用
收藏
页码：163 / 172
页数：9
相关论文
共 308 条
  • [1] Woyach JA(2012)Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features Leukemia 26 1442-1444
  • [2] Lozanski G(2008)Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 5446-5456
  • [3] Ruppert AS(2011)The double life of a B-1 cell: self-reactivity selects for protective effector functions Nat Rev Immunol 11 34-46
  • [4] Lozanski A(2006)Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status Leukemia 20 1774-1782
  • [5] Blum KA(1999)Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 94 1840-1847
  • [6] Jones JA(2008)Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia Blood 112 1923-1930
  • [7] Hallek M(2005)Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells J Clin Invest 115 1797-1805
  • [8] Cheson BD(2009)High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia Blood 114 4675-4686
  • [9] Catovsky D(2002)Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression Proc Natl Acad Sci USA 99 6955-6960
  • [10] Caligaris-Cappio F(2011)Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL Leukemia 25 1452-1458
12345678910